CA2740557C - Annexin and its use to treat inflammatory disorders - Google Patents

Annexin and its use to treat inflammatory disorders Download PDF

Info

Publication number
CA2740557C
CA2740557C CA2740557A CA2740557A CA2740557C CA 2740557 C CA2740557 C CA 2740557C CA 2740557 A CA2740557 A CA 2740557A CA 2740557 A CA2740557 A CA 2740557A CA 2740557 C CA2740557 C CA 2740557C
Authority
CA
Canada
Prior art keywords
annexin
sepsis
treatment
variant
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2740557A
Other languages
English (en)
French (fr)
Other versions
CA2740557A1 (en
Inventor
Paul Arnold
Xiangru Lu
Qingping Feng
Original Assignee
London Health Sciences Centre Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42106169&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2740557(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by London Health Sciences Centre Research Inc filed Critical London Health Sciences Centre Research Inc
Publication of CA2740557A1 publication Critical patent/CA2740557A1/en
Application granted granted Critical
Publication of CA2740557C publication Critical patent/CA2740557C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2740557A 2008-10-17 2009-10-16 Annexin and its use to treat inflammatory disorders Active CA2740557C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10639008P 2008-10-17 2008-10-17
US61/106,390 2008-10-17
PCT/CA2009/001469 WO2010043045A1 (en) 2008-10-17 2009-10-16 Annexin and its use to treat inflammatory disorders

Publications (2)

Publication Number Publication Date
CA2740557A1 CA2740557A1 (en) 2010-04-22
CA2740557C true CA2740557C (en) 2020-04-14

Family

ID=42106169

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2740557A Active CA2740557C (en) 2008-10-17 2009-10-16 Annexin and its use to treat inflammatory disorders

Country Status (6)

Country Link
US (1) US9192649B2 (enExample)
EP (1) EP2349321B1 (enExample)
JP (1) JP5590621B2 (enExample)
CN (1) CN102256617B (enExample)
CA (1) CA2740557C (enExample)
WO (1) WO2010043045A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2740557C (en) 2008-10-17 2020-04-14 London Health Sciences Centre Research Inc. Annexin and its use to treat inflammatory disorders
WO2010069605A2 (en) 2008-12-19 2010-06-24 Medirista Biotechnologies Ab Oxidized cardiolipin as a novel pro-inflammatory factor
WO2011160845A2 (en) 2010-06-24 2011-12-29 Medirista Biotechnologies Ab Oxidized phospholipids and lipoproteins, and antibodies thereto, as biomarkers of inflammatory conditions and methods of treatment
CN102690345B (zh) * 2011-03-24 2014-03-19 江苏靶标生物医药研究所有限公司 人膜联蛋白v变体及其表达、制备和应用
HUE042929T2 (hu) * 2011-06-15 2019-07-29 Resother Pharma Aps Gyulladáscsökkentõ gyógyszerészeti termékek
IN2014DN07022A (enExample) * 2012-02-21 2015-04-10 Inst Nat Sante Rech Med
JP2015513535A (ja) 2012-02-21 2015-05-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ウイルス侵入補助因子としてのｔｉｍレセプター
WO2014077575A1 (ko) * 2012-11-13 2014-05-22 다인바이오 주식회사 덱에이 효소반응으로 조제한 항비만 및 항당뇨 효능을 갖는 한천 유래 네오아가로올리고당 복합 조성물
GB2542391A (en) * 2015-09-17 2017-03-22 Annexin Pharmaceuticals Ab Process of manufacture
GB201702144D0 (en) * 2017-02-09 2017-03-29 Annexin Pharmaceuticals Ab Therapeutic compositions
WO2019238550A1 (en) * 2018-06-12 2019-12-19 Universiteit Maastricht Method for the treatment of hypoxic-ischemic encephalopathy in newborns
CN109529017B (zh) * 2018-12-25 2022-06-14 江苏靶标生物医药研究所有限公司 一种膜联蛋白v的应用
US11357823B2 (en) * 2019-08-30 2022-06-14 Suzhou Yabao Pharmaceutical R&D Co., Ltd Method for treating cerebral stroke
US20220193192A1 (en) * 2019-08-30 2022-06-23 Suzhou Yabao Pharmaceutical R&D Co Ltd Methods of treating a traumatic brain injury
CN112057623A (zh) * 2020-06-03 2020-12-11 江苏靶标生物医药研究所有限公司 一种磷脂酰丝氨酸在制备治疗炎症性肠病药物中的应用
WO2022073134A1 (en) * 2020-10-09 2022-04-14 London Health Sciences Centre Research Inc. Annexin a5 compositions and methods
CN112618696B (zh) * 2020-12-14 2023-05-05 南京大学 Annexin A5在制备治疗胆汁淤积药物中的应用
CN115245559A (zh) * 2021-04-25 2022-10-28 上海萨美细胞技术有限公司 一种用于治疗肺损伤的药物
CN117186239A (zh) * 2022-01-30 2023-12-08 南京瑞初医药有限公司 融合蛋白及其应用
CN118001375A (zh) * 2023-04-12 2024-05-10 上海萨美细胞技术有限公司 一种用于难愈性创面修复的药物
CN119097689A (zh) * 2023-06-08 2024-12-10 上海萨美细胞技术有限公司 一种用于治疗卵巢功能不全的药物
CN118001372A (zh) * 2023-07-04 2024-05-10 上海萨美细胞技术有限公司 膜联蛋白在抗衰老中的用途
WO2025086968A1 (zh) * 2023-10-25 2025-05-01 上海萨美细胞技术有限公司 一种用于治疗肺纤维化的药物
WO2025129329A1 (en) * 2023-12-23 2025-06-26 London Health Sciences Centre Research Inc. Methods for treatment of sepsis
CN118203650B (zh) * 2024-01-26 2025-04-29 上海萨丽斐生物科技有限公司 一种用于治疗色素沉着的药物
CN118846001B (zh) * 2024-07-09 2025-09-02 上海萨丽斐生物科技有限公司 一种具有保湿、修护、紧致、抗皱功效的组合物及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0339285A3 (en) 1988-03-31 1989-11-29 RORER INTERNATIONAL (OVERSEAS) INC. (a Delaware corporation) Recombinant endonexin ii
US5229367A (en) 1991-01-21 1993-07-20 Sclavo S.P.A. Antiinflammatory peptide derived from human lipocortin V
CA2185535C (en) 1994-04-11 2000-10-24 Christiaan Peter Maria Reutelingsperger A method for detecting and/or optionally quantifying and/or separating apoptotic cells in or from a sample
US7645739B2 (en) 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
US20030152513A1 (en) 2001-09-06 2003-08-14 Imetrix, Inc. Intravascular delivery of therapeutic and imaging agents to stressed and apoptotic cells using annexin V as a targeting vector
JP4444821B2 (ja) 2002-06-06 2010-03-31 ツェ・チェイン・ウン 遺伝子組み換えによる新しい抗凝血性蛋白質
PT1755642E (pt) 2004-04-15 2010-04-20 Athera Biotechnologies Ab Anexina v para prevenção de aterotrombose e da ruptura de placas
WO2009001224A2 (en) 2007-06-22 2008-12-31 Eth Zurich Antivirals
WO2009018500A1 (en) * 2007-07-31 2009-02-05 The Johns Hopkins University Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
PL2234631T3 (pl) 2007-12-18 2013-03-29 Athera Biotechnologies Ab Związki i metody stosowane w terapii choroby naczyniowej
HUE044621T2 (hu) * 2008-02-22 2019-11-28 Annexin Pharmaceuticals Ab Vegyületek és eljárások resztenózis megelõzésére vagy kezelésére
CA2740557C (en) 2008-10-17 2020-04-14 London Health Sciences Centre Research Inc. Annexin and its use to treat inflammatory disorders
MA41020A (fr) * 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome

Also Published As

Publication number Publication date
JP5590621B2 (ja) 2014-09-17
CN102256617A (zh) 2011-11-23
JP2012505837A (ja) 2012-03-08
US9192649B2 (en) 2015-11-24
EP2349321A1 (en) 2011-08-03
US20120014920A1 (en) 2012-01-19
EP2349321B1 (en) 2020-04-22
CA2740557A1 (en) 2010-04-22
WO2010043045A1 (en) 2010-04-22
EP2349321A4 (en) 2012-12-19
CN102256617B (zh) 2015-04-08

Similar Documents

Publication Publication Date Title
CA2740557C (en) Annexin and its use to treat inflammatory disorders
KR102113809B1 (ko) 조직 재생을 유도하기 위한 펩티드 및 그의 이용
JP6002727B2 (ja) 末梢循環への骨髄由来多能性幹細胞動員薬
EP2707014B1 (en) High-affinity, dimeric inhibitors of psd-95 and their use for treating ischemic brain damage and pain
JP6227601B2 (ja) 好中球活性化に起因する疾患の治療薬及び検査方法
JP2019514895A (ja) 新規な免疫原性ＣＤ１ｄ結合ペプチド
JP2025124629A (ja) 治療用融合タンパク質
KR20150110460A (ko) 골수세포-1 상에 발현되는 촉발 수용체(ｔｒｅｍ－１) trem-유사 전사체 1(ｔｌｔ－１)로부터 유도되는 억제 펩타이드 및 그의 용도
TW202142254A (zh) 用於治療或預防纖維化、肥大或心臟衰竭之骨髓源性生長因子
EP3599245A1 (en) Il-17a binding polypeptides and medical uses thereof
JP2012512170A (ja) 血管バリア機能の促進および肺線維症の治療する組成物および方法
US9139615B2 (en) High-affinity, dimeric inhibitors of PSD-95 as efficient neuroprotectants against ischemic brain damage and for treatment of pain
Wang et al. Macrophage migration inhibitory factor derived from spinal cord is involved in activation of macrophages following gecko tail amputation
WO2006059777A1 (ja) アルツハイマー治療剤
CZ303409B6 (cs) Zkrácený a mutovaný lidský chemokin
WO2016176493A1 (en) Treatment of medical conditions
KR102549282B1 (ko) 시알산화된 면역글로불린을 유효성분으로 포함하는 염증성 질환의 치료용 조성물
WO2007072980A1 (ja) アペリンの新規用途
Rainer et al. Cardiomyocyte-specific TGFβ suppression blocks neutrophil infiltration, augments multiple cytoprotective cascades, and reduces early mortality after myocardial infarction
US20180193437A1 (en) Compositions and methods for reducing organ rejection by reducing heparan sulfate in donor transplants
Abdelaziz The Protective Effects of Remote Ischaemic Preconditioning on Pressure Overload-Induced Myocardial Remodelling
CA3251109A1 (en) S100A1 PROTEIN INTENDED FOR USE IN THE TREATMENT AND PREVENTION OF PROLONGED HEART ATTACKS
JP2007137774A (ja) 抗炎症剤及びエンドトキシンショック抑制剤
Scofield et al. EXTRACELLULAR UBIQUITIN AFFECTS CARDIAC FIBROBLAST FUNCTION AND PROLIFERATION
HK1240598B (zh) 用於诱导组织再生的肽及其应用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20141016